UB Paderborn / Katalog / Suche / in CDI

HDL and cardiovascular disease

The Lancet (British edition), 2014-08, Vol.384 (9943), p.618-625

2014

Volltextzugriff (PDF)

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340

2015

Volltextzugriff (PDF)

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.341-350

2015

Volltextzugriff (PDF)

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

The Lancet (British edition), 2015-05, Vol.385 (9983), p.2153-2161

2015

Volltextzugriff (PDF)

Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2014-10, Vol.64 (14), p.1418-1426

2014

Volltextzugriff (PDF)

Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1513-1515

2017

Volltextzugriff (PDF)

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

The American journal of cardiology, 2014-06, Vol.113 (12), p.2018-2020

2014

Volltextzugriff (PDF)

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Journal of clinical lipidology, 2017-01, Vol.11 (1), p.195-203.e4

2017

Volltextzugriff (PDF)

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

The lancet. Diabetes & endocrinology, 2014-06, Vol.2 (6), p.455-463

2014

Volltextzugriff (PDF)

Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.602-616

2017

Volltextzugriff (PDF)

Children with hypercholesterolemia of unknown cause: Value of genetic risk scores

Journal of clinical lipidology, 2016-07, Vol.10 (4), p.851-859

2016

Volltextzugriff (PDF)

Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia

Journal of clinical lipidology, 2017-03, Vol.11 (2), p.507-514

2017

Volltextzugriff (PDF)

Statins in Familial Hypercholesterolemia

Journal of the American College of Cardiology, 2016-07, Vol.68 (3), p.252-260

2016

Volltextzugriff (PDF)

The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia

The American heart journal, 2015-05, Vol.169 (5), p.736-742.e1

2015

Volltextzugriff (PDF)

Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency

Journal of clinical lipidology, 2015-05, Vol.9 (3), p.396-399

2015

Volltextzugriff (PDF)

The Value of Screening for Carotid Plaque in Patients Referred for Echocardiography

Canadian journal of cardiology, 2014-10, Vol.30 (10), p.1148-1149

2014

Volltextzugriff (PDF)

Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema

Clinical therapeutics, 2008-12, Vol.30 (12), p.2314-2323

2008

Volltextzugriff (PDF)

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

Journal of the American College of Cardiology, 2014-08, Vol.64 (5), p.485-494

2014

Volltextzugriff (PDF)

Reply

Journal of the American College of Cardiology, 2015, Vol.65 (1), p.109-109

2015

Volltextzugriff (PDF)

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.840-840

2017

Volltextzugriff (PDF)

The Genetics of High-Density Lipoprotein Metabolism: Clinical Relevance for Therapeutic Approaches

The American journal of cardiology, 2009-11, Vol.104 (10), p.22E-31E

2009

Volltextzugriff (PDF)

Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging

Journal of the American College of Cardiology, 2011-12, Vol.58 (24), p.2481-2487

2011

Volltextzugriff (PDF)

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

The lancet. Diabetes & endocrinology, 2017-04, Vol.5 (4), p.280-290

2017

Volltextzugriff (PDF)

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

The lancet. Diabetes & endocrinology, 2016-10, Vol.4 (10), p.850-861

2016

Volltextzugriff (PDF)

Compromised LCAT function is associated with increased atherosclerosis

Circulation (New York, N.Y.), 2005-08, Vol.112 (6), p.879-884

2005

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

HDL and cardiovascular disease

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation in Familial Hypercholesterolemia

Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms

Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia

Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study

Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit

Children with hypercholesterolemia of unknown cause: Value of genetic risk scores

Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia

Statins in Familial Hypercholesterolemia

The effect of an apolipoprotein A-I–containing high-density lipoprotein–mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia

Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency

The Value of Screening for Carotid Plaque in Patients Referred for Echocardiography

Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: Two clinical trials in healthy volunteers and patients with hereditary angioedema

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

Reply

Durability of Alirocumab Effect: Data From an Open-Label Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

The Genetics of High-Density Lipoprotein Metabolism: Clinical Relevance for Therapeutic Approaches

Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

Compromised LCAT function is associated with increased atherosclerosis

Suchergebnisse filtern